AR079494A1 - Composiciones organicas para tratar las enfermedades relacionadas con el factor de choque por calor 1 hsf1 - Google Patents
Composiciones organicas para tratar las enfermedades relacionadas con el factor de choque por calor 1 hsf1Info
- Publication number
- AR079494A1 AR079494A1 ARP100104667A ARP100104667A AR079494A1 AR 079494 A1 AR079494 A1 AR 079494A1 AR P100104667 A ARP100104667 A AR P100104667A AR P100104667 A ARP100104667 A AR P100104667A AR 079494 A1 AR079494 A1 AR 079494A1
- Authority
- AR
- Argentina
- Prior art keywords
- hsf1
- sense chain
- rnai agent
- composition
- nucleotides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
Abstract
La presente divulgacion se refiere a métodos para el tratamiento de enfermedades relacionadas con HSF1, tales como cáncer y enfermedades virales, utilizando una cantidad terapéuticamente efectiva de un agente de ARNi para HSF. Reivindicacion 1: Una composicion que comprende un agente de ARNi, el cual comprende una cadena en sentido y una cadena anti-sentido, en donde la cadena anti-sentido comprende cuando menos 15 nucleotidos contiguos que difieren por 0, 1, 2, o 3 nucleotidos de la cadena anti-sentido de un agente de ARNi para HSF1 proporcionado en la Tabla 1 o en la Tabla 2 o en la Tabla 3 o en la Tabla 3A o en la Tabla 8 o en la Tabla 9A o en la Tabla 9B. Reivindicacion 2: La composicion de la reivindicacion 1, en donde la composicion comprende además un segundo agente de ARNi para HSF1. Reivindicacion 13: La composicion de la reivindicacion 1, en donde el agente de ARNi se liga a uno o más de: compuesto de diagnostico, grupo reportero, agente reticulante, fraccion que confiere resistencia a la nucleasa, nucleobase natural o inusual, molécula lipofílica, colesterol, lípido, lectina, esteroide, uvaol, hecigenina, diosgenina, terpeno, triterpeno, sarsasapogenina, Friedelina, ácido litocolico derivado de epifriedelanol, vitamina, carbohidrato, dextrano, pululano, quitina, quitosano, carbohidrato sintético, oligo-lactato 15-mer, polímero natural, polímero molecular de peso bajo o mediano, inulina, ciclodextrina, ácido hialuronico, proteína, agente de enlace de proteína, molécula de direccion a integrina, péptido policationico, poliamina, mimético de péptido, y/o transferrina. Reivindicacion 41: Un método para el tratamiento de una enfermedad relacionada con HSF1 en un individuo, el cual comprende el paso de administrar al individuo una cantidad terapéuticamente efectiva de una composicion que comprende un agente de ARNi, el cual comprende una cadena en sentido y una cadena anti-sentido, en donde la cadena anti-sentido comprende cuando menos 15 nucleotidos contiguos que difieren por 0, 1, 2, o 3 nucleotidos de la cadena anti-sentido de un agente de ARNi para HSF1 proporcionado en la Tabla A1 o en la Tabla 8 o en la Tabla 9A o en la Tabla 9B. Reivindicacion 43: El método de la reivindicacion 41, en donde la enfermedad relacionada con HSF1 es un cáncer seleccionado a partir de la lista de cánceres de vejiga, oseo, de mama, cervical, de colon, colo-rectal, endometrial, fibrosarcoma, gástrico, hematopoiético, intestinal, de rinon, hígado, pulmon, linfoma, neuroectodérmico, neuroblastoma, sarcoma de Ewing, osteosarcoma, de ovario, páncreas, pleura, prostata, piel, de células escamosas, de estomago, y testicular, leucemia, leucemia promielocítica, y enfermedad de Hodgkin. Reivindicacion 72: Un método para inhibir la expresion de HSF1 en una célula, el cual comprende el paso de introducir en la célula una composicion que comprende un agente de ARNi, el cual comprende una cadena en sentido y una cadena anti-sentido, en donde la cadena anti-sentido comprende cuando menos 15 nucleotidos contiguos que difieren por 0, 1, 2, o 3 nucleotidos de la cadena antisentido de un agente de ARNi para HSF1 proporcionado en la Tabla 1, en la Tabla 2, en la Tabla 3, en la Tabla 3A, o en la Tabla 8 o en la Tabla 9A o en la Tabla 9B.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28813709P | 2009-12-18 | 2009-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR079494A1 true AR079494A1 (es) | 2012-02-01 |
Family
ID=43646461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100104667A AR079494A1 (es) | 2009-12-18 | 2010-12-16 | Composiciones organicas para tratar las enfermedades relacionadas con el factor de choque por calor 1 hsf1 |
Country Status (14)
Country | Link |
---|---|
US (8) | US8293718B2 (es) |
EP (4) | EP3766976A1 (es) |
JP (2) | JP5819848B2 (es) |
KR (2) | KR101718297B1 (es) |
CN (2) | CN105125572A (es) |
AR (1) | AR079494A1 (es) |
AU (1) | AU2010332881B2 (es) |
BR (1) | BR112012014760A2 (es) |
CA (2) | CA2784783C (es) |
HK (1) | HK1214949A1 (es) |
MX (3) | MX339050B (es) |
TW (1) | TWI576108B (es) |
UY (1) | UY33114A (es) |
WO (1) | WO2011073326A2 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113862361A (zh) * | 2021-10-25 | 2021-12-31 | 中山大学孙逸仙纪念医院 | 一种诊断和治疗膀胱癌的分子标志物hsf1及其用途 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE427352T1 (de) | 2002-07-26 | 2009-04-15 | Novartis Vaccines & Diagnostic | Modifizierte kleine irns molekule und methoden zu deren anwendung |
EP1796732B1 (en) * | 2004-10-01 | 2013-10-30 | Novartis Vaccines and Diagnostics, Inc. | Modified small interfering rna molecules and methods of use |
US8765704B1 (en) | 2008-02-28 | 2014-07-01 | Novartis Ag | Modified small interfering RNA molecules and methods of use |
US8293718B2 (en) | 2009-12-18 | 2012-10-23 | Novartis Ag | Organic compositions to treat HSF1-related diseases |
WO2013030778A2 (en) | 2011-09-02 | 2013-03-07 | Novartis Ag | Organic compositions to treat hsf1-related diseases |
US10023862B2 (en) | 2012-01-09 | 2018-07-17 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat beta-catenin-related diseases |
SG10201704611WA (en) * | 2012-12-13 | 2017-07-28 | Aduro Biotech Inc | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
GB201317609D0 (en) | 2013-10-04 | 2013-11-20 | Cancer Rec Tech Ltd | Inhibitor compounds |
DK3119888T3 (da) | 2014-03-19 | 2021-09-06 | Ionis Pharmaceuticals Inc | Sammensætninger til at modulere ataxin-2-ekspression |
GB201505658D0 (en) | 2015-04-01 | 2015-05-13 | Cancer Rec Tech Ltd | Inhibitor compounds |
GB201617103D0 (en) | 2016-10-07 | 2016-11-23 | Cancer Research Technology Limited | Compound |
FR3082274B1 (fr) | 2018-06-06 | 2021-11-19 | Gaztransport Et Technigaz | Cuve etanche et thermiquement isolante |
EP3826645A4 (en) | 2018-07-25 | 2023-05-17 | Ionis Pharmaceuticals, Inc. | COMPOUNDS AND METHODS FOR REDUCING ATXN2 EXPRESSION |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6696561B1 (en) | 1909-07-09 | 2004-02-24 | Basf Aktiengesellschaft | Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US5030453A (en) | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5032401A (en) | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
US7053052B2 (en) * | 1997-01-21 | 2006-05-30 | Voellmy Richard W | Therapies involving mutated heat shock transcription factor |
US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
AR013269A1 (es) | 1997-08-04 | 2000-12-13 | Scras | Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
SK287538B6 (sk) | 1998-03-20 | 2011-01-04 | Commonwealth Scientific And Industrial Research Organisation | Syntetický gén obsahujúci dispergovanú alebo cudzorodú deoxyribonukleovú molekulu, génový konštrukt obsahujúci tento syntetický gén a prípravok obsahujúci tento syntetický gén |
AUPP249298A0 (en) * | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
ATE507299T1 (de) | 1998-04-08 | 2011-05-15 | Commw Scient Ind Res Org | Verfahren und mittel zum erhalt von veränderten phänotypen |
US6342596B1 (en) * | 1998-05-05 | 2002-01-29 | Hsf Pharmaceuticals S.A. | Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
AU776150B2 (en) | 1999-01-28 | 2004-08-26 | Medical College Of Georgia Research Institute, Inc. | Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
EP2363478B1 (en) | 1999-04-21 | 2019-07-24 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhibiting the function of polynucleotide sequences |
CN1360631A (zh) | 1999-07-09 | 2002-07-24 | 美国家用产品公司 | 在质粒序列转录过程中防止畸变rna形成的方法和组合物 |
WO2001029058A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
WO2001038551A1 (en) | 1999-11-29 | 2001-05-31 | Cold Spring Harbor Laboratory | Regulation of polycomb group gene expression for increasing seed size in plants |
RU2164944C1 (ru) | 1999-12-09 | 2001-04-10 | Институт молекулярной биологии им. В.А. Энгельгардта РАН | Способ изменения генетических свойств организма |
WO2001049844A1 (en) | 1999-12-30 | 2001-07-12 | Rutgers, The State University Of New Jersey | Compositions and methods for gene silencing |
IT1316982B1 (it) | 2000-01-17 | 2003-05-26 | Univ Roma | Isolamento e caratterizzazione di un gene per il silenziamento genicoda n.crassa e suoi usi. |
CA2403397A1 (en) | 2000-03-16 | 2001-09-20 | Genetica, Inc. | Methods and compositions for rna interference |
GB2377221B (en) | 2000-03-17 | 2004-08-18 | Benitec Australia Ltd | Genetic silencing |
EP2319864A3 (de) | 2000-03-22 | 2012-11-21 | Sanofi-Aventis Deutschland GmbH | Nematodes as model organisms for the investigation of neurodegenerative diseases, in particular parkinson's disease, use and method |
GB0007268D0 (en) | 2000-03-24 | 2000-05-17 | Cyclacel Ltd | Cell cycle progression proteins |
WO2001075164A2 (en) | 2000-03-30 | 2001-10-11 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
US20100305186A1 (en) | 2000-05-30 | 2010-12-02 | Johnson & Johnson Research Pty Limited | Methods for mediating gene suppression |
US6680068B2 (en) | 2000-07-06 | 2004-01-20 | The General Hospital Corporation | Drug delivery formulations and targeting |
ATE405585T1 (de) | 2000-11-09 | 2008-09-15 | Cenix Bioscience Gmbh | Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen |
TR200401292T3 (tr) * | 2000-12-01 | 2004-07-21 | Max@Planck@Gesellschaft�Zur�F�Rderung�Der�Wissenschaften | RNAÁgirişimineÁyolÁaçanÁküçükÁRNAÁmolekülleri |
EP1399189A1 (en) | 2001-06-11 | 2004-03-24 | Universite De Montreal | Compositions and methods for enhancing nucleic acid transfer into cells |
WO2003000861A2 (en) | 2001-06-22 | 2003-01-03 | The Regents Of The University Of California | Eukaryotic genes involved in adult lifespan regulation |
JP5170934B2 (ja) | 2001-08-16 | 2013-03-27 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 改良dnaリポフェクションならびに/または徐放性プロドラッグおよび薬物療法のための試薬の合成と使用 |
ATE508188T1 (de) | 2002-02-01 | 2011-05-15 | Life Technologies Corp | Oligonukleotid-zusammensetzungen mit verbesserter wirksamkeit |
WO2004002453A1 (en) | 2002-06-28 | 2004-01-08 | Protiva Biotherapeutics Ltd. | Method and apparatus for producing liposomes |
WO2004029213A2 (en) | 2002-09-28 | 2004-04-08 | Massachusetts Institute Of Technology | Compositions and methods for delivery of short interfering rna and short hairpin rna |
JP2006507841A (ja) | 2002-11-14 | 2006-03-09 | ダーマコン, インコーポレイテッド | 機能的siRNAおよび超機能的siRNA |
US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
CA2507125C (en) | 2002-11-25 | 2014-04-22 | Masafumi Matsuo | Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors |
DE60332277D1 (de) | 2002-11-26 | 2010-06-02 | Univ Massachusetts | Verabreichung von sirnas |
WO2004064731A2 (en) | 2003-01-14 | 2004-08-05 | University Of Washington | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymlplhoid tissues |
CA2524255C (en) | 2003-03-21 | 2014-02-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
AU2004257373B2 (en) | 2003-07-16 | 2011-03-24 | Arbutus Biopharma Corporation | Lipid encapsulated interfering RNA |
MXPA06002216A (es) | 2003-08-28 | 2006-04-27 | Novartis Ag | Interferencia de arn doble que tiene extremos romos y modificaciones 3'. |
US20070218551A1 (en) * | 2003-10-02 | 2007-09-20 | Chuan-Yuan Li | Novel Sirna-Based Approach to Target the Hif-Alpha Factor for Gene Therapy |
CA2566286A1 (en) * | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same |
US7795419B2 (en) * | 2004-05-26 | 2010-09-14 | Rosetta Genomics Ltd. | Viral and viral associated miRNAs and uses thereof |
US7740861B2 (en) | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
EP4272748A3 (en) | 2004-06-28 | 2024-03-27 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
CN101184839A (zh) | 2005-04-08 | 2008-05-21 | 纳斯泰克制药公司 | 用于呼吸道病毒感染的RNAi治疗 |
US8354384B2 (en) | 2005-06-23 | 2013-01-15 | Yale University | Anti-aging micrornas |
US20090062222A1 (en) | 2005-09-29 | 2009-03-05 | Trustees Of Boston University | Methods for Sensitizing Cancer Cells to Inhibitors |
EP1948674A4 (en) | 2005-11-02 | 2009-02-04 | Protiva Biotherapeutics Inc | MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF |
US7919603B2 (en) * | 2005-12-19 | 2011-04-05 | New York University | Heat shock RNA |
US20090011004A1 (en) | 2005-12-30 | 2009-01-08 | Philadelphia Health & Education Corp., D/B/A/ Drexel University Of College Of Medicine | Improved carriers for delivery of nucleic acid agents to cells and tissues |
GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
WO2008022035A2 (en) | 2006-08-10 | 2008-02-21 | The Scripps Research Institute | Methods for identifying cellular modulators of disaggregation activity or aggregation activity in an animal |
CN101200721B (zh) * | 2006-09-18 | 2011-06-08 | 复旦大学附属中山医院 | 人心肌保护基因及其用途 |
US7972870B2 (en) * | 2007-02-02 | 2011-07-05 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3 |
US7858592B2 (en) * | 2007-02-26 | 2010-12-28 | The Board Of Regents Of The University Of Texas System | Interfering RNAs against the promoter region of P53 |
WO2008141074A1 (en) | 2007-05-10 | 2008-11-20 | Salk Institute For Biological Studies | Identification of compounds that protect against amyloid diseases |
MY153691A (en) | 2007-05-22 | 2015-03-13 | Arcturus Therapeutics Inc | Hydroxymethyl substituted rna oligonucleotides and rna complexes |
AR066984A1 (es) | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
CA2697055A1 (en) * | 2007-08-21 | 2009-02-26 | Scott And White Memorial Hospital And Scott, Sherwood And Brindley Found Ation | Methods and compositions for post-transcriptional gene silencing |
WO2009082817A1 (en) | 2007-12-27 | 2009-07-09 | Protiva Biotherapeutics, Inc. | Silencing of polo-like kinase expression using interfering rna |
WO2009103067A2 (en) * | 2008-02-14 | 2009-08-20 | The Children's Hospital Of Philadelphia | Compositions and methods to treat asthma |
WO2011005786A2 (en) * | 2009-07-06 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for enhancing production of a biological product |
US8293718B2 (en) * | 2009-12-18 | 2012-10-23 | Novartis Ag | Organic compositions to treat HSF1-related diseases |
-
2010
- 2010-12-16 US US12/970,268 patent/US8293718B2/en active Active
- 2010-12-16 BR BR112012014760A patent/BR112012014760A2/pt not_active IP Right Cessation
- 2010-12-16 EP EP20192418.0A patent/EP3766976A1/en active Pending
- 2010-12-16 CN CN201510486187.5A patent/CN105125572A/zh active Pending
- 2010-12-16 KR KR1020167006895A patent/KR101718297B1/ko active IP Right Grant
- 2010-12-16 JP JP2012543756A patent/JP5819848B2/ja active Active
- 2010-12-16 EP EP18182635.5A patent/EP3406720A1/en not_active Withdrawn
- 2010-12-16 CA CA2784783A patent/CA2784783C/en active Active
- 2010-12-16 AR ARP100104667A patent/AR079494A1/es unknown
- 2010-12-16 KR KR1020127018714A patent/KR101605932B1/ko not_active IP Right Cessation
- 2010-12-16 EP EP10792928A patent/EP2513309A2/en not_active Withdrawn
- 2010-12-16 CA CA3112716A patent/CA3112716A1/en active Pending
- 2010-12-16 WO PCT/EP2010/069917 patent/WO2011073326A2/en active Application Filing
- 2010-12-16 AU AU2010332881A patent/AU2010332881B2/en active Active
- 2010-12-16 MX MX2012007032A patent/MX339050B/es active IP Right Grant
- 2010-12-16 MX MX2017007968A patent/MX369004B/es unknown
- 2010-12-16 CN CN201080057690.4A patent/CN102686729B/zh active Active
- 2010-12-16 EP EP15192568.2A patent/EP3000885B1/en active Active
- 2010-12-16 MX MX2015013656A patent/MX348526B/es unknown
- 2010-12-17 UY UY33114A patent/UY33114A/es not_active Application Discontinuation
- 2010-12-17 TW TW099144666A patent/TWI576108B/zh not_active IP Right Cessation
-
2012
- 2012-02-01 US US13/363,504 patent/US8623838B2/en active Active
- 2012-02-01 US US13/363,493 patent/US8481509B2/en active Active
-
2013
- 2013-10-15 US US14/054,166 patent/US9096637B2/en active Active
-
2015
- 2015-06-22 US US14/746,148 patent/US9540643B2/en active Active
- 2015-10-01 JP JP2015195916A patent/JP5981625B2/ja active Active
-
2016
- 2016-03-14 HK HK16102909.8A patent/HK1214949A1/zh unknown
- 2016-11-23 US US15/359,894 patent/US10287582B2/en active Active
-
2019
- 2019-05-14 US US16/411,805 patent/US11091761B2/en active Active
-
2022
- 2022-04-06 US US17/714,272 patent/US20220380775A1/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113862361A (zh) * | 2021-10-25 | 2021-12-31 | 中山大学孙逸仙纪念医院 | 一种诊断和治疗膀胱癌的分子标志物hsf1及其用途 |
CN113862361B (zh) * | 2021-10-25 | 2023-08-15 | 中山大学孙逸仙纪念医院 | 一种诊断和治疗膀胱癌的分子标志物hsf1及其用途 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR079494A1 (es) | Composiciones organicas para tratar las enfermedades relacionadas con el factor de choque por calor 1 hsf1 | |
JP2013514321A5 (es) | ||
Wang et al. | Sustained miRNA delivery from an injectable hydrogel promotes cardiomyocyte proliferation and functional regeneration after ischaemic injury | |
JP2014525435A5 (es) | ||
JP2015517466A5 (es) | ||
Gong et al. | Arabinogalactan derived from Lycium barbarum fruit inhibits cancer cell growth via cell cycle arrest and apoptosis | |
JP2013525332A5 (es) | ||
JP2015503608A5 (es) | ||
WO2012112690A3 (en) | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains | |
Gao et al. | Knockdown of galectin-1 facilitated cisplatin sensitivity by inhibiting autophagy in neuroblastoma cells | |
BR112012011294A2 (pt) | composição nutritiva para promover o equilíbrio de microbiotas do intestino e a saúde | |
WO2008109105A3 (en) | Methods and compositions for improved therapeutic effects with sirna | |
BR112012024564A2 (pt) | anticorpos contra csf-1r | |
WO2013170272A3 (en) | Site-specific labeling and targeted delivery of proteins for the treatment of cancer | |
CN106795096A (zh) | 用于递送核酸的新型脂质和脂质纳米颗粒制剂 | |
JP2018536689A5 (es) | ||
JP2016511256A5 (es) | ||
EP4253395A3 (en) | Processes for the preparation of carbohydrate conjugated rna agents | |
TN2011000416A1 (en) | Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient | |
Akim et al. | Understanding hyaluronan receptor (CD44) interaction, HA-CD44 activated potential targets in cancer therapeutics | |
WO2013101983A3 (en) | Targeted self-assembly 0f functionalized carbon nanotubes on tumors | |
Yue et al. | A polysaccharide from Agaricus blazei attenuates tumor cell adhesion via inhibiting E-selectin expression | |
WO2012046943A3 (ko) | 재조합된 유전자발현 조절서열을 가지는 종양 특이적 발현이 개선된 유전자 전달체 | |
PE20141909A1 (es) | Terapia combinada para el tratamiento del cancer de ovario | |
IN2014MN01886A (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |